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Sodium metabolism by the kidney is accomplished by an intricate interaction between signals from extrarenal and intrarenal
sources and between antinatriuretic and natriuretic factors. Renal dopamine plays a central role in this interactive network. The
natriuretic hormones, such as the atrial natriuretic peptide,mediate some of their effects by affecting the renal dopaminergic system.
Renal dopaminergic tonus can be modulated at different steps of dopamine metabolism (synthesis, uptake, release, catabolism, and
receptor sensitization) which can be regulated by the atrial natriuretic peptide. At tubular level, dopamine and atrial natriuretic
peptide act together in a concerted manner to promote sodium excretion, especially through the overinhibition of Na+, K+-ATPase
activity. In this way, different pathological scenarios where renal sodium excretion is dysregulated, as in nephrotic syndrome or
hypertension, are associated with impaired action of renal dopamine and/or atrial natriuretic peptide, or as a result of impaired
interaction between these two natriuretic systems. The aim of this review is to update and comment on the most recent evidences
demonstrating how the renal dopaminergic system interacts with atrial natriuretic peptide to control renal physiology and blood
pressure through different regulatory pathways.
1. Introduction
Renal sodium retention, a major determinant of hyper-
tension, is regulated by a variety of endocrine, autocrine,
and neuronal factors [1]. These factors regulate sodium
metabolism by controlling the rate of sodium reabsorption
at different tubular segments of the kidney [1]. According to
Aperia A, wemust consider the possibility that antinatriuretic
as well as natriuretic factors may use common signal-
ing pathways to increase or decrease natriuresis involving,
respectively, the reversible activation or deactivation of the
enzyme Na+, K+-ATPase in renal tubules [2].
Besides its well known role as a brain neurotransmitter,
dopamine exerts specific functions at the periphery, with
the most relevant effects being those on the cardiovascular
system and the kidney [2, 3]. In 1964, it was reported that
dopamine increases the glomerular filtration rate and pro-
motes sodium excretion, and in 1972 the role of dopamine as a
relevant autocrine and paracrine regulator of renal functions
was reported for the first time [4, 5]. After that, several
reports clearly demonstrated that the intrarenal synthetized
dopamine constitutes a peripheral dopaminergic system and
that renal dopamine is amodulator of blood pressure, sodium
balance, and renal functions, independently of the neural
dopaminergic system [3]. The importance of dopamine as
a natriuretic hormone is reflected through its capacity to
inhibit themajority of renal tubule sodium transporters [2, 6].
Notably, the activity ofNa+, K+-ATPase is inhibited inmost of
the tubular segments by dopamine, where it acts by opposing
the effects of antinatriuretic factors, such as angiotensin II
(ANG II) [6, 7].
The atrial natriuretic peptide (ANP) discovered by de
Bold et al. is a 28-amino acid peptide synthesized and
stored in the atrial myocytes and released in response to
the stretching of the cardiac wall or after stimulation with
endothelin, citokines, or 𝛼-adrenergic agents [8–10]. ANP
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Figure 1: Major processes that regulate the endogenous content of dopamine in renal tubular cells and the renal dopaminergic tonus. B0:
amino acid transport system B0; COMT: catechol-O-methyltransferase; LATs: L-type amino acid transporters; MAO: monoamine-oxidase;
OCTs: organic cationic transporters; OCTNs: organic cation/carnitine transporters; VMATs: vesicular monoamine transporters.
natriuretic effects are exerted by increasing the glomerular
filtration rate and by inhibiting sodium tubular reabsorption
[11]. In the proximal tubular cells, ANP inhibits ANG II
sodium andwater dependent reabsorption and also decreases
water reabsorption by distal and collector tubules [12]. The
inhibitory effects of ANP are mediated by a cyclic guanylate
monophosphate- (cGMP-) protein kinase G- (PKG-) depen-
dent mechanism [13].
2. Renal Dopamine: Function and Regulation
Steps of a Local Natriuretic System
Renal dopaminergic tonus can be modulated by the avail-
ability of intrarenal dopamine, which depends on the fol-
lowing: (a) the precursor L-Dopa that filters through the
glomerulus and then is uptaken by the proximal tubules;
(b) the synthesis of dopamine that is dependent on Dopa
decarboxylase activity; (c) the release of dopamine from the
tubular cell to the tubular fluid; (d) the uptake of dopamine
from the circulation to the tubular cell; (e) the amount
of dopamine storage into specific vesicles; (f) the activity
of catechol-O-methyltransferase (COMT) and monoamine-
oxidase (MAO), which are the catabolizing enzymes of
dopamine (Figure 1) [14, 15].
Renal dopamine derives mainly from the local synthesis
in the kidney. The dopamine precursor L-Dopa enters into
the cells carried inward by sodium dependent and indepen-
dent transporters [16]. After this, L-Dopa is converted into
dopamine by Dopa decarboxylase, also named aromatic L-
amino acid decarboxylase, which is present in high concen-
trations in the proximal tubular cells [17]. Unlike that in
neural tissue, the dopamine synthesized by the renal tubules
is not converted into norepinephrine [18]. The conversion of
L-Dopa into dopamine in the kidneys provides virtually all
the free urinary dopamine [19]. L-Dopa uptake by the proxi-
mal tubule cells is stimulated by Na+-independent and Na+-
dependent transporters through the apical membrane [20].
The inward Na+ gradient apparently stimulates the apical
Na+-dependent L-Dopa influx via a Na+-dependent L-Dopa
transporter, namely, amino acid transport system B0 (sys-
tem B0) [20–24]. This linkage between L-Dopa uptake and
sodium transport explains why urinary dopamine increases
after a high salt intake [20]. Therefore, L-Dopa uptake can
be controlled by changes in salt intake [17]. In this way, it
has been demonstrated that sodium retention leads to an
increase in renal dopaminergic tonus, and the natriuretic
effects of dopamine aremore prominent under this condition.
The inhibition or the downregulation of dopamine recep-
tors significantly attenuates the natriuretic response to salt
loading [2].TheNa+-independent mechanism involves other
two transporters, namely, type 1 and type 2 L-amino acid
transporters (LAT-1 and LAT-2, resp.), placed mainly on the
lumen side of the proximal tubular cells [20]. L-Dopa supply
to the proximal tubules increases dopamine local synthesis
and consequently influences renal dopaminergic tonus. In
agreement with this, it has been demonstrated that the acute
administration of L-Dopa or 𝛾-glutamyl L-Dopa (gludopa)
increases the natriuresis, which is dopamine dependent, and
simultaneously inhibits renal tubule Na+, K+-ATPase activity
[25]. The inhibition of Dopa decarboxylase by carbidopa
prevents the response of dopamine to sodium loading in
both rats and humans and stimulatesNa+, K+-ATPase activity
[14, 26]. Dopa decarboxylase activity can be modulated by
different regulatory factors. The enzyme can be upregulated
by a high salt diet and downregulated by a low salt diet [27].
In this way, a salt loading to the kidneys results in an increase
of Dopa decarboxylase activity in the proximal tubules [28].
Another fact to be considered is that urinary dopamine
excretion, natriuresis, and diuresis are elevated in an animal
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model characterized by a moderate volume expansion, with
these effects being reduced by the administration of a Dopa
decarboxylase inhibitor (benserazide) [29]. Additionally, it
has been demonstrated that the administration of carbidopa
suppressed the basal Dopa decarboxylase-specific activity by
98% in renal cortex slices, suggesting that the decarboxylation
activity belonged to Dopa decarboxylase and not to other
decarboxylating enzymes [30]. This effect was associated
with an increase of 56% in the Na+, K+-ATPase activity
[31]. Similarly, ANG II reduces Dopa decarboxylase activity
by 48% and under dopamine synthesis inhibition ANG II
increases Na+, K+-ATPase activity by 35% [30, 31].
Besides L-Dopa transporters located in the proximal
tubular cells, other nonneuronal transporters have been
postulated as candidates for dopamine transport at the same
location. Newly formed intracellular dopamine leaves the
cell through the apical border by a diffusional process,
whereas plasma dopamine can be uptaken through the basal
cell border by a saturable process [32]. Both processes are,
however, insensitive to the classical inhibitors of dopamine
transporters, such as cocaine and GBR-12909 [32, 33]. Non-
neuronal transporters can handle different exogenous and
endogenous organic cations (with different affinities and
kinetics) and still remain a subject of intense research up to
date. Renal organic transporters are members of the group
SLC22A (solute carrier superfamily), which includes the
polyspecific organic cationic transporters: OCT-1, OCT-2,
and OCT-3, located mainly at the basolateral membrane of
proximal tubular cells, and OCTN-1, OCTN-2, and OCTN-
3 located mainly at the apical side of the proximal tubular
cells [32, 34, 35]. Among the catecholamines, dopamine is
one of the endogenous organic cations to be uptaken or
secreted by this kind of transporters [36]. A possible route
for dopamine handling in the proximal tubules includes
a two-step procedure: first, the electrogenic uptake of cir-
culating dopamine at the basolateral membrane, mediated
by OCTs, and second, the cation release at the luminal
membrane, which is mediated by an electroneutral proton
cation antiporter (OCTNs) [32, 37]. In this way, the OCT-
2 appears to be the mainly basolateral transporter involved
in the efflux of dopamine into the tubular lumen, since the
intravenous administration of a potent inhibitor of OCT-2,
Disprocynium 24, significantly reduces the tubular secretion
of dopamine while it increases its spillover into the systemic
circulation [38–40]. The physiological relevance of OCTs on
dopamine handling in the kidney is linked to their regulation
by protein kinase phosphorylations and by natriuretic and
antinatriuretic hormones [41].
Aperia and coworkers were the first to publish in 1987
that renal synthetized dopamine, acting as a first messenger,
was capable of regulating the activity of tubular Na+, K+-
ATPase through a short term mechanism [42]. Dopamine
inhibition of Na+, K+-ATPase and other tubular sodium
transporters was then confirmed by different experimental
studies [6]. Through this mechanism, most of the hormonal
factors related to sodium excretion exert their natriuretic
actions [2, 14, 31, 43].These evidences permit concluding that
renal sodium metabolism depends on an intact intrarenal
dopaminergic system.
3. Regulation of Renal Dopamine System by
the Atrial Natriuretic Peptide
Although renal dopamine can exert direct natriuretic effects
by itself, it is possible that the amine can increase sodium
excretion through indirect effects by adding its effects to
other natriuretic hormones and opposing the antinatriuretic
actions of other endogenous factors [31, 44]. Diverse mecha-
nisms have been postulated to explain the putative interaction
between renal dopamine and other hormones to regulate
sodium excretion by the kidney [43, 44]. In this way, two
major pathways have been involved. The first includes short-
time and synergistic effects of renal dopamine, which can
potentiate natriuretic ANP effects by one side or antagonize
vasopressin actions or alpha adrenergic receptor stimulation
by the other side [45–47].The second pathway involves long-
term effects, by which renal dopamine can increase sodium
excretion by upregulating the synthesis of prostaglandins or
by downregulating the expression of AT1 receptors [48, 49].
The observation that dopamine and ANP share some
similar physiological effects suggests that each one may
contribute by itself to enhance the actions of the other
[50]. Diverse experimental studies have suggested a possible
interaction between natriuretic peptide hormones and the
renal dopaminergic system [15, 51, 52]. However, besides
these reports, the mechanisms involved in ANP-dopamine
interaction in the kidney remain unclear up to date and are
still under study.
It has been reported that part of the inhibitory effects
of ANP on sodium and water reabsorption is dependent on
dopaminergic mechanisms, particularly those that involve
the dopamine receptors [53–55]. Marin-Grez et al. andWebb
et al. have reported that part of ANP inhibitory effects on
sodium and water reabsorption is mediated by dopaminergic
mechanisms, since haloperidol and the D
1
receptor antag-
onist SCH 23390 partially blocked a significant percentage
of the natriuretic and diuretic effects of ANP [53, 55]. In
a similar fashion, ANP can modulate the metabolism of
another catecholamine like noradrenaline, since it has been
demonstrated thatANP increases norepinephrine uptake and
its endogenous content and decreases its release, synthe-
sis, and turnover and tyrosine hydroxylase activity at the
hypothalamic presynaptic nerve ending level [56, 57]. The
natriuretic peptides also regulate norepinephrinemetabolism
in the adrenal medulla [58]. Then, it is likely that ANP
could regulate DA metabolism in the kidney as it does in
the central nervous system and adrenal medulla. To support
the idea that ANP may interact with renal dopamine to
facilitate its actions, different experimental studies demon-
strated that ANP enhances the inhibitory effect of dopamine
on the Na+/H+ exchanger in the proximal tubules and also
induces the recruitment ofD
1
receptors from the intracellular
compartment to the plasma membrane, thereby facilitating
their stimulation by dopamine [2, 59, 60]. Another study
that complements and reinforces this idea showed that ANP
stimulates dopamine uptake by the tubular cells in the kidney,
via the stimulation of natriuretic peptide receptor type A
(NPR-A) receptors coupled to guanylate cyclase, followed by
cGMP (as second messenger) and protein kinase G (PKG)
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activation [17, 43]. This uptake process was characterized as
a typical extraneuronal uptake and temperature dependent
mechanism [43]. In addition, one in vitro study demonstrated
that ANP increases Dopa decarboxylase activity by 42% in
renal cortex slices (unpublished data) (Figure 2).
ANP also reduces COMT activity but lacks effect on renal
dopamine release [52]. These findings altogether show that
ANP contributes to increase endogenous dopamine content
in the renal external cortex and points out that both systems
interact to enhance their natriuretic and diuretic effects.
ANP and dopamine systems, through their second mes-
sengers and associated protein kinases or protein phos-
phatases, initiate a cascade of events ultimately resulting in
the phosphorylation and inhibition of the enzymatic activity
of Na+, K+-ATPase [2, 17, 43].
In this way, ANP favors dopamine intracellular accu-
mulation, which in turn permits D
1
receptors recruitment
and stimulation, resulting in the overinhibition of Na+, K+-
ATPase activity, the decrease of sodium reabsorption, and
the increase of natriuresis [17]. In agreement with this,
it has been demonstrated that, under dopamine synthesis
inhibition, dopamine and ANP added simultaneously signif-
icantly decrease Na+, K+-ATPase activity by 50%with respect
to dopamine or ANP alone [17]. Moreover, the addition
of hydrocortisone (an extraneuronal dopamine transporter
inhibitor) reversed ANP-dopamine overinhibition of the
enzyme, demonstrating thatANP enhances dopamine uptake
through tubular transporters (Figure 3) [17].Thus, dopamine
and ANP may achieve their effects through a common
pathway that involves reversible deactivation of renal tubular
Na+, K+-ATPase activity [17, 43]. The signaling pathway
mechanism by which these two hormones enhance their
natriuretic action could involve the dopamine and cAMP-
regulated phosphoprotein (DARPP-32).The knockout of this
intracellular messenger in mice leads to a hypertensive state
where ANP cannot exert its natriuretic action [61]. It must
be pointed out that PKG and PKC, activated by ANP and
dopamine, respectively, stimulate DARPP-32 phosphoryla-
tion, which in turn induces the inactivation of Na+, K+-
ATPase [17, 62]. This suggests that DARPP-32 may also be
involved in the modulation and interaction of ANP and
dopamine renal systems [61, 62].
Controversially, other authors suggested that there is
no relationship between ANP and dopamine systems [63].
Murphy and Bass reported that it is unlikely that dopamine
generation or release, or dopamine receptor activation (with
the possible exception of its involvement in the rat), is essen-
tial to express ANP effects. They postulate that dopamine
actions do not depend on ANP release and that there are
no studies about dopamine activation of ANP receptors [63].
On the other hand, Hirata et al. suggested that the renal
effects of ANP and dopamine utilize different pathways,
since ANP and DA effects on both glomerular filtration
rate and sodium urinary excretion are additive. They also
reported that, in contrast to dopamine, ANP increased
arterioles efferent resistance and nephrogenous cGMP [64].
A complementary study carried out in humans demonstrated
that the infusion of a low dose of ANP (1.5 pmol/kg/min)
did not produce hemodynamic or natriuretic effects, but
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Figure 2: Effects of 200𝜇M carbidopa and 100 nM ANP on
dopamine formed as the product of Dopa decarboxylase-specific
activity (nmol/mg of protein per minute ± SEM) on in vitro study
using homogenates from rat renal cortex slices (n: number of
samples); ∗𝑃 < 0.005 versus control; ∗∗𝑃 < 0.05 versus control.
Control group: 𝑛 = 7; carbidopa group: 𝑛 = 6; ANP group: 𝑛 = 6.
a higher dose (15 pmol/kg/min) increased urinary sodium
excretion, but is lacking hemodynamic actions. In addition,
the administration of both doses of ANP did not alter urinary
dopamine excretion [65].
The described interaction between circulating ANP and
locally formed dopamine should contribute to the mainte-
nance of a well-balanced regulation of sodium metabolism
and blood pressure. The impairment of this relationship may
also play a relevant role in the pathophysiology of experi-
mental and human hypertension. In this way, the possibility
that altered uptake of dopamine by renal tubules could be
contributing to the development of essential hypertension
might be considered.
4. Atrial Natriuretic
Peptide and Dopamine Interaction:
Pathophysiological Implications
Sodium retention is one of the main features of hypertension
[66]. Renal dopamine is critical for the preservation of
a normal hydroelectrolyte balance, a steady redox state,
and normal blood pressure levels [18]. Experimental and
clinical studies indicate that the impairment of the renal
dopaminergic system plays a major role in the pathogenesis
of different types of hypertension [67–69]. On the other hand,
renal dopamine receptors can modulate the production of
reactive oxygen species (ROS), by interacting with the renin-
angiotensin and sympathetic nervous systems [3]. In the last
years, several experimental studies demonstrated the role
of oxidative stress and its association with the impairment
of dopamine receptor functions in the pathophysiology of
hypertension [68, 70–72]. Hypertension can be associated
with the absence of any of the five dopamine receptor
subtypes [68, 70, 71]. Dopamine, through stimulation of D
1
,
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D
2
, and D
5
receptors, regulates the redox balance and exerts
antioxidant effects by direct and indirect inhibition of proox-
idant enzymes, such as nicotinamide adenine dinucleotide
phosphate reduced form (NADPH) oxidase, and stimulation
of antioxidant enzymes, which in turn may also indirectly
inhibit NADPH oxidase activity [68, 70]. In this way, acti-
vation of dopamine D
2
receptor inhibits NADPH oxidase
activity by increasing the expression of endogenous antioxi-
dants, like Parkinson protein 7 (PARK7 orDJ-1), paraoxonase
2 (PON2), and heme oxygenase 2 (HO-2) [68]. Furthermore,
stimulation of the D
5
receptor decreases NADPH oxidase
activity by inhibition of phospholipase D
2
and increases
the expression of the antioxidant HO-1 [68]. Meanwhile,
the D
1
receptor inhibits NADPH oxidase activity through
stimulation of the protein kinase A-protein kinase C cross-
talk [70, 71]. Another study demonstrated that oxidative stress
via nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-𝜅B) activation downregulates D
1
receptor function
causing a decrease in sodium excretion, which contributed
to an increase in blood pressure [72]. This was confirmed
by the fact that inhibition of oxidative stress and NF-𝜅B
activation through stimulation of a redox-sensitive transcrip-
tion factor (nuclear factor E
2
-related factor 2- (Nrf2-) phase
II antioxidant enzyme pathway) by sulforaphane maintains
D
1
receptor functionality and prevents the development of
hypertension [72]. Atrial natriuretic peptide, produced and
released by myocytes in response to high blood pressure,
can suppress renin-angiotensin system and reduce water and
sodium loads on the circulatory system to diminish blood
pressure levels [73]. Several studies indicate that, in addition
to these effects, ANP can act to preserve renal function
[74, 75]. Koga et al. showed in rats that ANP also has
antioxidant effects as demonstrated by its ability to attenuate
ROS levels in a renal ischemia-reperfusion injury model
[76]. In another study using uremic rats by 5/6 nephrectomy,
progression of renal deterioration and renal oxidative stress
was accompanied with an increase of ANP mRNA 133-fold
in tandem with the increase in blood pressure, suggesting
thatANPmRNAmay be increased as a protectivemechanism
[73]. Taking this evidence into consideration, renoprotective
effects of ANP and dopamine combination must be further
investigated.
The proteinuria (>3.5 g/day) and sodium retention
observed in nephrotic syndrome conduce to the development
and maintenance of edema and ascites [77]. Besides
hypovolemia and hypoalbuminemia, a primary abnormality
in intrarenal sodium handling is also implicated in the
nephrotic syndrome [77, 78]. It has been demonstrated
that this impairment of sodium excretion in the nephrotic
syndrome is due to an increase in the Na+/H+ exchanger
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(NHE3) activity in the proximal tubules, together with
a shift of NHE3 from an inactive to an active form [79].
Furthermore, other authors have attributed this disturbance
to a blunted response to ANP and also to an increase of
Na+, K+-ATPase activity at the cortical collecting duct
level [80, 81]. In addition, Sampaio-Maia and coworkers
showed a decrease in renal Dopa decarboxylase activity
with lower urinary excretion of dopamine and a reduced
availability of D
1
receptors in proximal tubules as a sign of
impairment of the renal dopaminergic system in rats with
puromycin aminonucleoside- (PAN-) nephrotic syndrome
[82]. The participation of D
1
receptors as a contributor
factor of sodium retention was supported by the fact that
the infusion of the D
1
receptor agonist fenoldopam was not
able to enhance the natriuretic response in PAN-nephrotic
syndrome rats or reverse Na+, K+-ATPase increased activity
under normal or volume expanded conditions [82]. Atrial
natriuretic peptide and intrarenal dopamine interact with
each other in the regulation of sodium homeostasis [51]. It is
noteworthy that, between other mechanisms of interaction,
ANP stimulates the recruitment and activation of silent
D
1
receptors from the cytosolic compartment towards the
plasmamembrane of renal tubular cells [83].The impairment
of ANP-dopamine interaction also contributes to sodium
retention in the experimental PAN-nephrotic syndrome
[51]. In this model, the unresponsiveness of ANP receptors
and the decrease of D
1
receptors expression in renal tubules
have been reported [51]. Although circulating ANP levels
in PAN-nephrotic syndrome are elevated, the increase
of natriuresis and urinary cGMP excretion evoked by an
acute volume expansion were blunted [51]. The fact that
the infusion of the phosphodiesterase type 5 inhibitor,
zaprinast, restored D
1
receptors in tubular cells, cGMP
urinary excretion, and natriuresis to control levels supports
the hypothesis of a dysfunction in ANP and D
1
receptors
in nephrotic syndrome [51]. The authors concluded that D
1
receptors may play a major role in ANP resistance observed
in PAN-nephrotic syndrome, since coadministration of
SCH-23390 (a D
1
receptor antagonist) abolished the effects
elicited by zaprinast [51].
5. Future Perspectives
Appropriate regulation of renal dopaminergic tonus is one
important requisite for the maintenance of sodium home-
ostasis and normal blood pressure. Identification of abnor-
malities in different steps of crucial importance for the reg-
ulation of the renal dopaminergic tonus should provide new
tools for early detection of individuals that are predisposed
to develop hypertension. Recently, it has been demonstrated
that renal gastrin and dopamine receptors interact to syner-
gistically increase sodium excretion and that the impairment
of this interaction may be involved in the pathogenesis of
hypertension [84]. Atrial natriuretic peptide, which targets
D
1
receptors at the plasma membrane and appears to have
many of its renal effects mediated via the D
1
receptor, could
open up new therapeutic possibilities.
Natriuretic peptides may exert beneficial effects on
nephrogenic diseases characterized by sodium and water
retention. In this way the clinical use of synthesized analogs
of natriuretic peptides such as anaritide, vasonatrin, ulari-
tide, and nesiritide must be considered in the future [85–
87]. Furthermore, pharmacological agents with dual action
(inhibitor/enhancer) on the renin-angiotensin and natri-
uretic peptide systems like omapatrilat have been used suc-
cessfully in clinical trials for hypertension treatment [88, 89].
Another fact is that the renal dopaminergic system is sen-
sitized by high salt intake and volume expansion, which raises
the question about how intrarenal sodium sensors influence
the bioavailability of renal dopamine. This approach may
lead to the development of new pharmacological strategies
in conditions of salt retention and hypertension. In this way,
it is important that drugs developed to enhance the renal
dopamine tonus are mainly targeting the kidney.
The recent awareness of the fact that dopamine has
beneficial renal effects that are opposed to oxidative stress and
inflammatory renal damage enables its use as a renoprotective
agent in the future. It ismandatory to carry out clinical studies
to demonstrate the participation of renal dopaminergic
system in pathological contexts involving impaired sodium
excretion as nephrotic syndrome or insulin resistance states.
Finally, novel physiological functions have been discovered
in recent years for natriuretic peptides, such as activation of
lipolysis, lipid oxidation, and mitochondrial respiration [90].
This could open a possible therapeutic intervention against
pandemic diseases such as obesity and insulin resistance.
6. Conclusions
Dopamine and ANP are involved in the management of
renal sodium excretion and in the pathophysiology of dif-
ferent kinds of experimental as well as human hypertension.
Current evidence suggests that there is a synergism between
the renal dopaminergic system and ANP to increase sodium
excretion. Atrial natriuretic peptide interacts with renal
dopaminergic system reinforcing its natriuretic and diuretic
effects through different mechanisms that favors dopamine
intracellular accumulation.The increment of endogenousDA
inside tubular cells would permit D
1
receptors recruitment
and stimulation and, in turn, overinhibition of Na+, K+-
ATPase activity.Thepossibility that impairedANP-dopamine
interaction by renal tubules may play a role in the pathogen-
esis of hypertension should be considered.
Sodium retention in nephrotic syndrome is attributed
to a blunted response to ANP and enhanced Na+, K+-
ATPase activity in the cortical collecting duct, suggesting that
dysfunction of renal dopaminergic and natriuretic peptide
systems contributes to sodium retention in the experimental
nephrotic syndrome. Both dopamine and ANP have protec-
tive effects on oxidative stress in the kidney. However, the
ultimate clinical importance of these effects remains to be
determined.
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